AGP Executive Report
Last update: 6 hours agoMS Treatment: A Swedish registry study of more than 9,200 people with relapsing-remitting multiple sclerosis found rituximab was linked to nearly 10 times the risk of inflammatory bowel disease. The absolute risk remained below 2% over 10 years. Severe Infections: Karolinska Institutet researchers traced antibodies linked to severe viral illness to different types of B cells in patients with COVID-19 and APS-1, a finding that could guide future diagnostics and treatments. Bloodstream Infections: A study spanning nine Skåne hospitals found immunosuppressed patients with bloodstream infections had higher short-term mortality and more resistant infections than other patients. Research Funding: Swedish Research Council grants will support projects at Karolinska Institutet on viral disease, brain organoids and hormone-disrupting chemicals; Wallenberg Foundation funding will back research into fibromyalgia’s biological mechanisms and potential treatments.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
